Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2025)
Historic Income from Continuing Operations for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$34.4 million.
- Amylyx Pharmaceuticals' Income from Continuing Operations rose 5270.41% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$148.9 million, marking a year-over-year increase of 4266.05%. This contributed to the annual value of -$301.4 million for FY2024, which is 71444.33% down from last year.
- Amylyx Pharmaceuticals' Income from Continuing Operations amounted to -$34.4 million in Q3 2025, which was up 5270.41% from -$41.4 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Income from Continuing Operations ranged from a high of $22.1 million in Q2 2023 and a low of -$118.8 million during Q1 2024
- In the last 5 years, Amylyx Pharmaceuticals' Income from Continuing Operations had a median value of -$35.9 million in 2025 and averaged -$34.3 million.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Income from Continuing Operations skyrocketed by 14080.75% in 2023, and later crashed by 765200.25% in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Income from Continuing Operations stood at -$28.3 million in 2021, then tumbled by 54.54% to -$43.8 million in 2022, then soared by 110.29% to $4.5 million in 2023, then crashed by 924.69% to -$37.2 million in 2024, then rose by 7.49% to -$34.4 million in 2025.
- Its Income from Continuing Operations was -$34.4 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$35.9 million in Q1 2025.